Mini drug pump for ophthalmic use

Transactions of the American Ophthalmological Society

Volumn 107, Issue , 2009, Pages 60-70

  Saati, Saloomeh ^a   Lo, Ronalee ^b   Li, Po Ying ^b   Meng, Ellis ^b   Varma, Rohit ^a   Humayun, Mark S ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b University of Southern California ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHENYLEPHRINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTERIOR EYE CHAMBER; ARTICLE; BIOCOMPATIBILITY; CANNULA; CONTROLLED DRUG RELEASE; DRUG DELIVERY SYSTEM; ELECTROLYSIS; EYE PHOTOGRAPHY; FLUORESCENCE ANGIOGRAPHY; GLAUCOMA; MICROELECTROMECHANICAL SYSTEM; MINIPUMP; NONHUMAN; PRIORITY JOURNAL; RABBIT; SLIT LAMP;

ANIMALS; ANTERIOR CHAMBER; COLORING AGENTS; CORNEA; DRUG DELIVERY SYSTEMS; ELECTROLYSIS; EQUIPMENT DESIGN; FEASIBILITY STUDIES; FLUORESCEIN ANGIOGRAPHY; MICROSCOPY, ELECTRON; OPHTHALMIC SOLUTIONS; OPHTHALMOLOGIC SURGICAL PROCEDURES; PROSTHESES AND IMPLANTS; RABBITS; SWINE; TRYPAN BLUE;

EID: 77949375544     PISSN: None     EISSN: 15456110     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Geroski DH, Edelhauser HF. Drug delivery for posterior segment eye disease. Invest Ophthalmol Vis Sci 2000;41:961-964.
2. Hoyng PF, van Beek LM. Pharmacological therapy for glaucoma: a review. Drugs 2000;59:411-434.
3. Hsu J. Drug delivery methods for posterior segment disease. Curr Opin Ophthalmol 2007;18:235-239.
4. Shell JW. Ophthalmic drug delivery systems. Surv Ophthalmol 1984;29:117-128.
5. Davies NM. Biopharmaceutical considerations in topical ocular drug delivery. Clin Exp Pharmacol Physiol 2000;27:558-562.
6. Sultana Y, Jain R, Aqil M, Ali A. Review of ocular drug delivery. Curr Drug Deliv 2006;3:207-217.
7. Bourlais CL, Acar L, Zia H, Sado PA, Needham T, Leverge R. Ophthalmic drug delivery systems - recent advances. Prog Retin Eye Res 1998;17:33-58.
8. Metrikin DC, Anand R. Intravitreal drug administration with depot devices. Curr Opin Ophthalmol 1994;5:21-29.
9. Ho QT, Kuo CJ. Vascular endothelial growth factor: biology and therapeutic applications. Int J Biochem Cell Biol 2007;39:1349-1357.
10. Lloyd R, Harris J, Wadhwa S, Chambers W. Food and Drug Administration approval process for ophthalmic drugs in the US. Curr Opin Ophthalmol 2008;19:190-194.
11. Ozkiris A, Erkilic K. Complications of intravitreal injection of triamcinolone acetonide. Can J Ophthalmol 2005;40:63-68.
12. Li P-Y, Shih J, Lo R, et al. An electrochemical intraocular drug delivery device. Sensors Actuators A Phys 2008;143:41-48.
13. Lo R, Li P-Y, Saati S, Agrawal R, Humayun MS, Meng E. A refillable microfabricated drug delivery device for treatment of ocular diseases. Lab Chip 2008;8:1027-1030.
14. Agrawal RN, He S, Spee C, Cui JZ, Ryan SJ, Hinton DR. In vivo models of proliferative vitreoretinopathy. Nat Protoc 2007;2:67-77.
15. Lattanzio FA Jr, Sheppard JD Jr, Allen RC, Baynham S, Samuel P, Samudre S. Do injections of 5-fluorouracil after trabeculectomy have toxic effects on the anterior segment? J Ocul Pharmacol Ther 2005;21:223-235.
16. Ethier CR, Johnson M, Ruberti J. Ocular biomechanics and biotransport. Annu Rev Biomed Eng 2004;6:249-273.
17. Alward WL. Medical management of glaucoma. N Engl J Med 1998;339:1298-1307.
18. Lad EM, Moshfeghi DM. Minimizing the risk of endophthalmitis following intravitreal injections. Compr Ophthalmol Update 2006;7:277-284; discussion 285-276.
19. Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006;113:1695 e1691-1615.
20. Bashshur ZF, Bazarbachi A, Schakal A, Haddad ZA, El Haibi CP, Noureddin BN. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 2006;142:1-9.
21. Costa RA, Jorge R, Calucci D, Melo LA Jr, Cardillo JA, Scott IU. Intravitreal bevacizumab (avastin) for central and hemicentral retinal vein occlusions: IBeVO study. Retina 2007;27:141-149.
22. Dash AK, Cudworth GC 2nd. Therapeutic applications of implantable drug delivery systems. J Pharmacol Toxicol Methods 1998;40:1-12.
23. Ambati J, Gragoudas ES, Miller JW, et al. Transscleral delivery of bioactive protein to the choroid and retina. Invest Ophthalmol Vis Sci 2000;41:1186-1191.
24. van den Berg A, Lammerink TSJ. Micro total analysis systems: microfluidic aspects, integration concept and applications. Topics Curr Chem 1997;194:21-49.
25. Shoji S. Fluids for sensor systems. Topics Curr Chem 1998;194:163-188.
26. Vilkner T, Janasek D, Manz A. Micro total analysis systems: recent developments. Analyt Chem 2004;76:3373-3385.
27. Razzacki SZ, Thwar PK, Yang M, Ugaz VM, Burns MA. Integrated microsystems for controlled drug delivery. Adv Drug Deliv Rev 2004;56:185-198.
28. Richards Grayson AC, Scheidt Shawgo R, Li Y, Cima MJ. Electronic MEMS for triggered delivery. Adv Drug Deliv Rev 2004;56:173-184.
29. Rodger DC, Wieland JD, Humayun MS, Tai YC. Scalable high lead-count parylene package for retinal prostheses. Sens Actuators B Chem 2006;117:107-114.
30. Wu HK, Huang B, Zare RN. Construction of microfluidic chips using polydimethylsiloxane for adhesive bonding. Lab Chip 2005;5:1393-1398.
31. Phillip M, Battelino T, Rodriguez H, Danne T, Kaufman F. Use of insulin pump therapy in the pediatric age-group: consensus statement from the European Society for Paediatric Endocrinology, the Lawson Wilkins Pediatric Endocrine Society, and the International Society for Pediatric and Adolescent Diabetes, endorsed by the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2007;30:1653-1662.
32. Ronn B, Mathiesen ER, Vang L, Lorup B, Deckert T. Evaluation of insulin pump treatment under routine conditions. Diabetes Res Clin Pract 1987;3:191-196.
33. Kim CS, Yim JH, Lee EK, Lee NH. Changes in corneal endothelial cell density and morphology after Ahmed glaucoma valve implantation during the first year of follow up. Clin Experiment Ophthalmol 2008;36:142-147.
34. Lim KS. Corneal endothelial cell damage from glaucoma drainage device materials. Cornea 2003;22:352-354.
35. van Dooren BT, Beekhuis WH, Pels E. Biocompatibility of trypan blue with human corneal cells. Arch Ophthalmol 2004;122:736-742.
36. Gloor B, Gloor ML, Merz-Hill M, Marshall J, Meszaros J, Daicker B. Wound healing of the corneal posterior surface in animal experiments. Klin Monatsbl Augenheilkd 1986;188:225-230.
37. Ichijima H, Petroll WM, Jester JV, et al. In vivo confocal microscopic studies of endothelial wound healing in rabbit cornea. Cornea 1993;12:369-378.
38. Olsen EG, Davanger M. The healing of rabbit corneal endothelium. Acta Ophthalmol (Copenh) 1984;62:796-807.
39. Van Horn DL, Sendele DD, Seideman S, Buco PJ. Regenerative capacity of the corneal endothelium in rabbit and cat. Invest Ophthalmol Vis Sci 1977;16:597-613.